The results of this trial conducted in anti-HBe and HBV-DNA positive chronic hepatitis indicate that lymphoblastoid interferon at this regimen may promote sustained termination of HBV replication and remission of liver disease, without a significant risk of relpase after withdrawal
Treatment of anti-HBe and HBV-DNA positive chronic hepatitis with lymphoblastoid interferon alfa.
FATTOVICH, Giovanna;
1992-01-01
Abstract
The results of this trial conducted in anti-HBe and HBV-DNA positive chronic hepatitis indicate that lymphoblastoid interferon at this regimen may promote sustained termination of HBV replication and remission of liver disease, without a significant risk of relpase after withdrawal
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
